The increased popularity of GLP-1 RAs and the unsettled association of thyroid hyperplasias and neoplasms prompted further investigation into the most recent US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data sets. The gene discussed is GLP1R; the disease is neoplasm.